German researchers who compared insulin lispro (Humalog) and insulin aspart (NovoLog) report that the two insulins are equally effective in controlling after-meal blood glucose in people with type 1 diabetes.
In a study funded by Novo Nordisk—the maker of NovoLog—24 people with type 1 diabetes were observed in a single-center, randomized, double-blind trial. The participants were given Humalog or NovoLog injections immediately before a standard mixed meal.
Blood-glucose excursions 4 hours and 6 hours after the meal were equivalent, as were maximum blood-glucose excursions.
—Diabetes Care, November 2002